 Exicure Incs NASDAQ: XCUR Audit Committee concluded that Grant Corbett misreported raw data from certain RD experiments related to XCUR-FXN preclinical program. Dr. Corbett misreported the results of at least three different experiments related solely to efficacy rather than safety. 